Literature DB >> 32197970

Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort.

Julia L M Dunn1, Tetsuo Shoda1, Julie M Caldwell1, Ting Wen1, Seema S Aceves2, Margaret H Collins3, Evan S Dellon4, Gary W Falk5, John Leung6, Lisa J Martin7, Paul Menard-Katcher8, Amanda K Rudman-Spergel9, Jonathan M Spergel10, Joshua B Wechsler11, Guang-Yu Yang12, Glenn T Furuta13, Marc E Rothenberg14.   

Abstract

BACKGROUND: There is strong evidence for a role of type 2 cytokines in the pathogenesis of eosinophilic esophagitis (EoE); however, heterogeneity in type 2 gene expression has not been examined.
OBJECTIVE: We examined type 2 immunity-associated gene expression in esophageal biopsy specimens, aiming to determine the degree of cytokine heterogeneity and its potential clinical significance.
METHODS: Patients (n = 312) were recruited from 10 sites associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. In addition to histologic and endoscopic assessment, esophageal biopsy specimens were examined for expression of 96 genes within the EoE diagnostic panel.
RESULTS: Five subgroups of patients with active EoE were identified by unsupervised clustering based on expression of IL4, IL5, IL13, C-C motif chemokine ligand 26 (CCL26), thymic stromal lymphopoietin (TSLP), Charcot-Leyden crystal (CLC), C-C motif chemokine receptor 3 (CCR3), and CPA3. These groups differed in age (P < .02) and EoE diagnostic panel score (P < 1.08E-30) but not in eosinophil levels. The group V patients had the highest expression of IL5, TSLP, and CCL26 and genes associated with tissue remodeling, such as COL8A1, actin γ-2 (ACTG2), and tetraspanin 12 (TSPAN12). IL5 and IL13 were highly expressed in group IV; however, groups IV and V differed in age (34 vs 14 years [P < .05]). Groups II and III, which exhibited intermediate expression of IL5 and CPA3, were differentiated by high TSLP and IL13 in group III.
CONCLUSION: We observed heterogeneous type 2 gene expression among patients with active EoE. Type 2 gene overexpression was not directly proportional to disease features; this was especially true for tissue remodeling events. These findings highlight a clinical opportunity for leveraging molecular endotypes to implement personalized medicine in EoE.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Allergy; IL-13; IL-5; T(H)2 cells; cytokine; eosinophil; fibrosis; inflammation; precision medicine; resolution

Mesh:

Substances:

Year:  2020        PMID: 32197970      PMCID: PMC7309223          DOI: 10.1016/j.jaci.2020.01.051

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  46 in total

1.  17β-Estradiol protects the esophageal epithelium from IL-13-induced barrier dysfunction and remodeling.

Authors:  Justin C Wheeler; Simone Vanoni; Chang Zeng; Lisa Waggoner; Yanfen Yang; David Wu; Jazib Uddin; Rebekah Karns; Leah Kottyan; Vincent Mukkada; Marc E Rothenberg; Simon P Hogan
Journal:  J Allergy Clin Immunol       Date:  2018-12-20       Impact factor: 10.793

2.  Suppressive effect of IL-4 on IL-13-induced genes in mouse lung.

Authors:  Fred D Finkelman; Mingyan Yang; Charles Perkins; Kathleen Schleifer; Alyssa Sproles; Joanna Santeliz; Jonathan A Bernstein; Marc E Rothenberg; Suzanne C Morris; Marsha Wills-Karp
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

3.  IL-4 induces IL-13-independent allergic airway inflammation.

Authors:  Charles Perkins; Marsha Wills-Karp; Fred D Finkelman
Journal:  J Allergy Clin Immunol       Date:  2006-08       Impact factor: 10.793

4.  Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.

Authors:  Alain M Schoepfer; Ekaterina Safroneeva; Christian Bussmann; Tanja Kuchen; Susanne Portmann; Hans-Uwe Simon; Alex Straumann
Journal:  Gastroenterology       Date:  2013-08-13       Impact factor: 22.682

5.  Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.

Authors:  Iris M Otani; Arjun A Anilkumar; Robert O Newbury; Monica Bhagat; Lisa Y Beppu; Ranjan Dohil; David H Broide; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2013-04-25       Impact factor: 10.793

6.  Allergic esophagitis in children: a clinicopathological entity.

Authors:  S V Walsh; D A Antonioli; H Goldman; V L Fox; A Bousvaros; A M Leichtner; G T Furuta
Journal:  Am J Surg Pathol       Date:  1999-04       Impact factor: 6.394

7.  Synaptopodin is upregulated by IL-13 in eosinophilic esophagitis and regulates esophageal epithelial cell motility and barrier integrity.

Authors:  Mark Rochman; Jared Travers; J Pablo Abonia; Julie M Caldwell; Marc E Rothenberg
Journal:  JCI Insight       Date:  2017-10-19

8.  Hierarchical IL-5 expression defines a subpopulation of highly differentiated human Th2 cells.

Authors:  Bhaskar Upadhyaya; Yuzhi Yin; Brenna J Hill; Daniel C Douek; Calman Prussin
Journal:  J Immunol       Date:  2011-08-17       Impact factor: 5.422

9.  Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children.

Authors:  Joshua B Wechsler; Scott M Bolton; Katie Amsden; Barry K Wershil; Ikuo Hirano; Amir F Kagalwalla
Journal:  Clin Gastroenterol Hepatol       Date:  2017-12-15       Impact factor: 11.382

10.  Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Authors:  Katherine Cheng; Sandeep K Gupta; Susanna Kantor; Jonathan T Kuhl; Seema S Aceves; Peter A Bonis; Kelley E Capocelli; Christina Carpenter; Mirna Chehade; Margaret H Collins; Evan S Dellon; Gary W Falk; Rashmi Gopal-Srivastava; Nirmala Gonsalves; Ikuo Hirano; Eileen C King; John Leung; Jeffrey P Krischer; Vincent A Mukkada; Alain Schoepfer; Jonathan M Spergel; Alex Straumann; Guang-Yu Yang; Glenn T Furuta; Marc E Rothenberg
Journal:  Transl Sci Rare Dis       Date:  2017-12-18
View more
  16 in total

Review 1.  Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine.

Authors:  Ian F Slack; Justin T Schwartz; Vincent A Mukkada; Shawna Hottinger; J Pablo Abonia
Journal:  Curr Allergy Asthma Rep       Date:  2020-06-06       Impact factor: 4.806

Review 2.  Intestinal eosinophils: multifaceted roles in tissue homeostasis and disease.

Authors:  G Coakley; H Wang; N L Harris
Journal:  Semin Immunopathol       Date:  2021-03-26       Impact factor: 9.623

Review 3.  Eosinophilic esophagitis: Immune mechanisms and therapeutic targets.

Authors:  Dilawar Khokhar; Sahiti Marella; Gila Idelman; Joy W Chang; Mirna Chehade; Simon P Hogan
Journal:  Clin Exp Allergy       Date:  2022-07-19       Impact factor: 5.401

4.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2022-05-20       Impact factor: 14.290

5.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  Gastroenterology       Date:  2022-05-20       Impact factor: 33.883

6.  Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study.

Authors:  Tetsuo Shoda; Margaret H Collins; Mark Rochman; Ting Wen; Julie M Caldwell; Lydia E Mack; Garrett A Osswald; John A Besse; Yael Haberman; Seema S Aceves; Nicoleta C Arva; Kelley E Capocelli; Mirna Chehade; Carla M Davis; Evan S Dellon; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Paneez Khoury; Amy Klion; Calies Menard-Katcher; John Leung; Vincent A Mukkada; Philip E Putnam; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Glenn T Furuta; Lee A Denson; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2022-01-25       Impact factor: 33.883

Review 7.  Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.

Authors:  Evan S Dellon; Dagmar Simon; Michael E Wechsler
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-12

8.  In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump.

Authors:  Eunice Odiase; Xi Zhang; Yan Chang; Melissa Nelson; Uthra Balaji; Jinghua Gu; Qiuyang Zhang; Zui Pan; Stuart Jon Spechler; Rhonda F Souza
Journal:  Gastroenterology       Date:  2021-02-11       Impact factor: 33.883

Review 9.  Eosinophils in Eosinophilic Esophagitis: The Road to Fibrostenosis is Paved With Good Intentions.

Authors:  Alfred D Doyle; Mia Y Masuda; Hirohito Kita; Benjamin L Wright
Journal:  Front Immunol       Date:  2020-12-01       Impact factor: 7.561

10.  RNA sequencing identifies global transcriptional changes in peripheral CD4+ cells during active oesophagitis and following epicutaneous immunotherapy in eosinophilic oesophagitis.

Authors:  Melanie A Ruffner; Zhe Zhang; Kelly Maurer; Amanda B Muir; Antonella Cianferoni; Kathleen E Sullivan; Jonathan M Spergel
Journal:  Clin Transl Immunology       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.